Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00035035 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

A Phase 3 study of Pancreatic Neoplasms and Metastases, Neoplasm, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
20
Study locations

NCT00035035: Completed Phase 3 study of Pancreatic Neoplasms and Metastases, Neoplasm, sponsored by Eli Lilly and Company.

NCT00035035 is a Phase 3 study of Pancreatic Neoplasms and Metastases, Neoplasm that has completed, run by Eli Lilly and Company. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00035035, a Phase 3 study of Pancreatic Neoplasms and Metastases, Neoplasm, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
20
Study locations

Study Summary

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

Conditions Studied

Pancreatic Neoplasms Metastases, Neoplasm

Interventions

  • DRUG ALIMTA
  • DRUG GEMZAR

Study Locations (20)

California

  • - Fountain Valley
  • - Fullerton
  • - Lancaster
  • - Los Angeles
  • - Pomona
  • - Santa Rosa
  • - Torrance

Illinois

  • - Chicago
  • - Decatur
  • - Harvey

Florida

  • - Lake Worth
  • - Miami

Kentucky

  • - Crestview Hills
  • - Louisville

Alabama

  • - Huntsville

Colorado

  • - Fort Collins

Connecticut

  • - Hartford

Indiana

  • - Indianapolis

Trial Details

FieldValue
Phase Phase 3
Eli Lilly and Company

1,341 total trials

What the finished NCT00035035 record still lists

NCT00035035 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which ALIMTA is the first listed.

NCT00035035 names 20 study sites across 10 states, led by California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT00035035 about?

NCT00035035 is a clinical study titled "A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.". Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their ...

What is the current status of trial NCT00035035?

This trial is currently completed. It is a Phase 3 study.

What conditions does trial NCT00035035 study?

This clinical trial studies the following conditions: Pancreatic Neoplasms, Metastases, Neoplasm.

What interventions are being tested in trial NCT00035035?

The interventions under investigation include: ALIMTA (DRUG), GEMZAR (DRUG).

Who is sponsoring clinical trial NCT00035035?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00035035 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00035035, the US trial registry maintained by the National Library of Medicine. NCT00035035 (unsized enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.